Shanghai - Delayed Quote CNY

WuXi AppTec Co., Ltd. (603259.SS)

42.92 +1.32 (+3.17%)
At close: April 26 at 3:00 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
NameTitlePayExercisedYear Born
Dr. Ge Li Ph.D. Co-Founder, Chairman, President & CEO -- -- 1967
Dr. Minzhang Chen Ph.D. Co-CEO & Executive Director -- -- 1969
Dr. Qing Yang Ph.D. Co-CEO & Executive Director -- -- 1969
Dr. Edward Hu M.B.A. Vice Chairman of the Board & Global Chief Investment Officer -- -- 1962
Ms. Ming Shi Senior VP & CFO -- -- 1974
Mr. Zhaohui Zhang COO of China, VP & Executive Director -- -- 1969
Mr. Yuanzhou Zhang Joint Company Secretary -- -- 1988
Mr. Ruijia Tang IR Director -- -- --
Dr. Howard Wu J.D. Senior VP, General Counsel & Global Head of Human Resources -- -- --
Dr. Jingchao Dong Ph.D. Senior VP & Head of RCS -- -- --

WuXi AppTec Co., Ltd.

288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai, 200131
China
86 21 5046 1111 https://www.wuxiapptec.com
Sector: 
Healthcare
Full Time Employees: 
41,116

Description

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

WuXi AppTec Co., Ltd.’s ISS Governance QualityScore as of April 1, 2024 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 9; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Jun 14, 2023
    Ex-Dividend Date

Upcoming Events

Apr 25, 2024 - Apr 26, 2024
WuXi AppTec Co., Ltd. Earnings Call